XtalPi subsidiary Ailux partners with Lilly for AI-driven antibody development

XtalPi Holdings Limited announced that its subsidiary, Shanghai Ailux Biotechnology Co., Ltd., has formed a strategic platform-based collaboration with Eli Lilly and Company. This partnership aims to advance the discovery and development of AI-driven bispecific antibodies for various diseases.

Under the terms, Lilly will access Ailux's AI-powered bispecific antibody engineering platform, which leverages advanced structural modeling, generative design, and developability analytics. The collaboration includes upfront and near-term milestone payments, potentially totaling tens of millions of US dollars, with an option for Lilly to license Ailux's proprietary platform for internal use.

The total potential value of the collaboration, encompassing development, regulatory, and commercial milestone payments, could reach up to $345 million. This agreement highlights Ailux's role as XtalPi's biologics innovation arm, focused on developing advanced biotherapeutics with AI-powered solutions.